Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/189102
Title: Bringing rehabilitation home with an e-health platform to treat stroke patients: study protocol of a randomized clinical trial (RGS@home)
Author: Mura, Anna
Maier, Martina
Rubio Ballester, Belén
Torre Costa, Javier de la
López Luque, Judit
Gelineau, Axelle
Mandigout, Stephane
Ghatan, Per Hamid
Fiorillo, Raffaele
Antenucci, Fabrizio
Coolen, Ton
Chivite, Iñigo
Callen, Antonio
Landais, Hugo
Gómez, OIga Irina
Melero, Cristina
Brandi, Santiago
Domenech, Marc
Daviet, Jean Christophe
Zucca, Riccardo
Verschure, Paul F. M. J.
Keywords: Assaigs clínics
Malalties cerebrovasculars
Rehabilitació
Telemàtica mèdica
Clinical trials
Cerebrovascular disease
Rehabilitation
Medical telematics
Issue Date: 20-Jun-2022
Abstract: Background: There is a pressing need for scalable healthcare solutions and a shift in the rehabilitation paradigm from hospitals to homes to tackle the increase in stroke incidence while reducing the practical and economic burden for patients, hospitals, and society. Digital health technologies can contribute to addressing this challenge; however, little is known about their effectiveness in at-home settings. In response, we have designed the RGS@home study to investigate the effectiveness, acceptance, and cost of a deep tech solution called the Rehabilitation Gaming System (RGS). RGS is a cloud-based system for delivering Al-enhanced rehabilitation using virtual reality, motion capture, and wearables that can be used in the hospital and at home. The core principles of the brain theory-based RGS intervention are to deliver rehabilitation exercises in the form of embodied, goal-oriented, and task-specific action.; Methods: The RGS@home study is a randomized longitudinal clinical trial designed to assess whether the combination of the RGS intervention with standard care is superior to standard care alone for the functional recovery of stroke patients at the hospital and at home. The study is conducted in collaboration with hospitals in Spain, Sweden, and France and includes inpatients and outpatients at subacute and chronic stages post-stroke. The intervention duration is 3 months with assessment at baseline and after 3, 6, and 12 months. The impact of RGS is evaluated in terms of quality of life measurements, usability, and acceptance using standardized clinical scales, together with health economic analysis. So far, one-third of the patients expected to participate in the study have been recruited (N = 90, mean age 60, days after stroke >= 30 days). The trial will end in July 2023.; Discussion: We predict an improvement in the patients' recovery, high acceptance, and reduced costs due to a soft landing from the clinic to home rehabilitation. In addition, the data provided will allow us to assess whether the prescription of therapy at home can counteract deterioration and improve quality of life while also identifying new standards for online and remote assessment, diagnostics, and intervention across European hospitals.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s13063-022-06444-0
It is part of: Trials, 2022, vol. 23, num. 518
URI: http://hdl.handle.net/2445/189102
Related resource: https://doi.org/10.1186/s13063-022-06444-0
ISSN: 1745-6215
Appears in Collections:Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))

Files in This Item:
File Description SizeFormat 
2022_Trials_Bringing_MuraA.pdf1.64 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons